Pharmacokinetics in Hemophilia Management and Personalization of Therapy

Downloadable slides with expert analysis on the importance of PK monitoring with EHL Factor VIII therapy for patients with hemophilia A.
Michael Callaghan, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 544 KB
Released: October 29, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Takeda Pharmaceuticals USA, LLC

Related Content

Commentary from Michael Callaghan, MD, on individualizing hemophilia prophylaxis with extended half-life products and PK profiling tools, from CCO

Michael Callaghan, MD Released: November 20, 2020

Janet L. Kwiatkowski, MD, MSCE, on current and emerging therapies for beta-thalassemia in a commentary from Clinical Care Options (CCO)

Janet L. Kwiatkowski, MD, MSCE Released: November 12, 2020

Gain key clinical insights fast, with this short slideset from CCO on the management of patients with hemophilia A with Factor VIII therapy

Michael Callaghan, MD Miguel A. Escobar, MD Guy A. Young, MD Released: November 5, 2020

Downloadable slides with expert analysis on managing CVD and other comorbidities in older patients with hemophilia A, from Clinical Care Options.

Miguel A. Escobar, MD Released: October 29, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue